With generics attacking Advair, GlaxoSmithKline has talked up prospects for 3-in-1 respiratory med Trelegy. Now, the company has data in hand that could help it move into the asthma arena—though it's ...

(Reuters) -British pharmaceutical giant GSK said on Wednesday it would cap out-of-pocket costs for all its inhaled asthma and chronic lung disease medicines at $35 per month for eligible patients in ...

LONDON (Reuters) - GlaxoSmithKline (GSK.L) is putting more marketing muscle behind its new lung drugs and is looking for a sales boost as top respiratory experts gather to analyse clinical trials data ...

GlaxoSmithKline is expecting flat earnings this year, having earlier forecast a decline, as rising sales of new drugs have helped offset the impact of generics on its Advair blockbuster in the US. The ...

Amid a Street-beating fourth-quarter report, GlaxoSmithKline quantified the hit that it’s been bracing for: Advair generics. If copycats launch midyear, as their makers hope, Glaxo figures its lead ...

LONDON (Reuters) - U.S. regulators have approved GlaxoSmithKline's three-in-one inhaler for chronic lung disease, a key new product for the group as it strives to keep its lead in respiratory medicine ...

March 20 (Reuters) - British pharmaceutical giant GSK said on Wednesday it would cap out-of-pocket costs for all its inhaled asthma and chronic lung disease medicines at $35 per month for eligible ...